Search the site

Fearless Mikayla: Why we research Down syndrome

Eight-year-old Mikayla is the miracle child her parents never thought they would have. They’d tried for seven years to have a baby, and when Mikayla was finally born they couldn’t contain their excitement or pride. The fact she had Down syndrome was secondary.

The Power of Why

Our job is to find the answers. It's helping us change kids' lives. See the "why?"s we're asking and answering.

Launching The Kids

Western Australia’s biggest and only medical research institute dedicated to improving kids’ health and wellbeing, has rebranded to The Kids Research Institute Australia.

Helping kids stay safe and strong online

Learn how our research is preventing cyberbullying and supporting kids’ mental wellbeing

The idea that changed kids’ health forever

Hear how one bold idea became a world-leading institute for kids’ health.

How April got her spark back after T1D diagnosis

Discover how our breakthroughs are helping kids with diabetes live longer, safer lives.

A diagnostic test for acute rheumatic fever (pilot study)

Currently there are no diagnostic tests for ARF, and no treatments targeting immune responses to improve disease outcomes.

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical

A phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety and tolerability of V114 in healthy infants (PNEULINK)

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical

A Phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine given as a series of 2 infant doses and 1 toddler dose in healthy infants (NeXXstep)

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical